A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Pomalidomide (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biomira USA
  • Most Recent Events

    • 08 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 08 Mar 2016 Planned primary completion date changed from 1 Oct 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 08 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top